SNYR vs ABUS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SNYR counters with relative strength in Valuation. Fundamentally, SNYR trades at 0.6x Forward P/E with -10.3% operating margin (-32.8% YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, SNYR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SNYR Revenue | ABUS Revenue | SNYR Op. Margin | ABUS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $10M | -14.5% | -1510.2% | SNYR |
| FY2019 | $30M | $10M | -27.1% | -2394.0% | SNYR |
| FY2020 | N/A | $10M | N/A | -836.1% | ABUS |
| FY2021 | N/A | $10M | N/A | -669.1% | ABUS |
| FY2022 | N/A | $40M | N/A | -167.8% | ABUS |
| FY2023 | $40M | $20M | 25.3% | -430.5% | SNYR |
| FY2024 | $30M | $10M | 16.7% | -1236.7% | SNYR |
| FY2025 | $30M | $10M | -27.8% | -271.0% | SNYR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SNYR | ABUS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1M | $623.9M | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | 0.6x | 3.6x | Lower Multiple | SNYR |
| Forward P/E Ratio Valuation | 0.6x | 10.2x | Lower Multiple | SNYR |
| Revenue Growth (YoY) Growth | -32.8% | -43.5% | Higher Growth | SNYR |
| Operating Margin (TTM) Profitability | -10.3% | 80.1% | Higher Margin | ABUS |
| Net Profit Margin Profitability | -57.0% | 121.2% | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | -361.1% | 269.6% | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 1% ($0โ$3) | 27% ($4โ$5) | Stronger Trend | ABUS |
| Beta / 30D Volatility Risk Regime | -0.86ฮฒ ยท 868% Vol | 1.04ฮฒ ยท 48% Vol | Lower Realized Risk | ABUS |
| Unified Institutional Score Composite Signal | 48.9 / 100 (HOLD) | 43.4 / 100 (HOLD) | Higher Composite | SNYR |